化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia):治療薬開発パイプライン動向2018

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIPR2016114)
◆英語タイトル:Chemotherapy Induced Neutropenia-Pipeline Insights, 2018
◆発行会社/調査会社:DelveInsight
◆商品コード:DIPR2016114
◆発行日:2018年12月
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:約60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後3営業日)
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia):治療薬開発パイプライン動向2018]についてメールでお問い合わせはこちら
※本調査レポートでは、世界における化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の薬剤リスト等をお届けしています。また、化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬開発に取り組んでいる企業情報も提供しています。

・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の概要

・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬パイプライン概要

・企業別開発中の化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬

・後期治験段階の薬剤(Filed & Phase III):比較分析

・中期治験段階の薬剤(Phase II):比較分析

・初期治験段階の薬剤(Phase I & IND Filed):比較分析

・前臨床段階の薬剤:比較分析

・薬剤候補のプロファイル

・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価

・開発が中止された薬剤リスト

・開発休止中の薬剤リスト

・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬開発に取り組んでいる企業リスト

・図表一覧
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s, “ Chemotherapy Induced Neutropenia-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Chemotherapy Induced Neutropenia. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Chemotherapy Induced Neutropenia. DelveInsight’s Report also assesses the Chemotherapy Induced Neutropenia therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitivepipeline landscape of Chemotherapy Induced Neutropenia
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


*** レポート目次(コンテンツ)***

Table of Contents
• Chemotherapy Induced Neutropenia Overview
• Chemotherapy Induced Neutropenia Pipeline Therapeutics
• Chemotherapy Induced Neutropenia Therapeutics under Development by Companies
• Chemotherapy Induced Neutropenia Filed and Phase III Products
• Comparative Analysis
• Chemotherapy Induced Neutropenia Phase II Products
• Comparative Analysis
• Chemotherapy Induced Neutropenia Phase I and IND Filed Products
• Comparative Analysis
• Chemotherapy Induced Neutropenia Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Chemotherapy Induced Neutropenia – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Chemotherapy Induced Neutropenia – Discontinued Products
• Chemotherapy Induced Neutropenia – Dormant Products
• Companies Involved in Therapeutics Development for Chemotherapy Induced Neutropenia
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Chemotherapy Induced Neutropenia, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Chemotherapy Induced Neutropenia Assessment by Monotherapy Products
• Chemotherapy Induced Neutropenia Assessment by Combination Products
• Chemotherapy Induced Neutropenia Assessment by Route of Administration
• Chemotherapy Induced Neutropenia Assessment by Stage and Route of Administration
• Chemotherapy Induced Neutropenia Assessment by Molecule Type
• Chemotherapy Induced Neutropenia Assessment by Stage and Molecule Type
• Chemotherapy Induced Neutropenia Therapeutics – Discontinued Products
• Chemotherapy Induced Neutropenia Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Chemotherapy Induced Neutropenia, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Chemotherapy Induced Neutropenia Assessment by Monotherapy Products
• Chemotherapy Induced Neutropenia Assessment by Combination Products
• Chemotherapy Induced Neutropenia Assessment by Route of Administration
• Chemotherapy Induced Neutropenia Assessment by Stage and Route of Administration
• Chemotherapy Induced Neutropenia Assessment by Molecule Type
• Chemotherapy Induced Neutropenia Assessment by Stage and Molecule Type


*** レポートのキーワード ***

化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)、治療薬、医薬品、薬剤、製薬企業、研究開発、治験、パイプライン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 硝酸ベリリウムの世界市場2018
    The Global Berylliumnitrate (CAS 13597-99-4) Industry 2018 Market Research Report is a professional and in-depth study on the current state of the Berylliumnitrate industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industr …
  • 脱毛剤(除毛剤)市場動向(~2017):フィンランド
    Synopsis The report presents detailed data on consumption trends in the Depilatories category in Finland, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers & acquisitions (of Skincare ma …
  • 公共施設の建設市場:日本
    This report is the result of Timetric’s extensive market research covering the institutional buildings construction industry in Japan. It contains detailed historic and forecast market value data for the institutional buildings construction industry, including a breakdown of the data by construction …
  • Hyundai Heavy Industries Co., Ltd. (9540) : 企業概要及びSWOT分析
    This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. WMI's 'Hyundai Heavy Industries Co., Ltd. (9540) : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondar …
  • コネクテッドホーム及びIoTの世界市場機会・予測2017 – 2022
    The Connected Home ecosystem is rapidly expanding beyond merely Connected Entertainment (TV, Receiver, DVD Recorder, Media Player, Gaming Consoles) to include many areas such as Home and Office Equipment (Printer, VoIP Phone, etc.), Personal Consumer Electronics (Wireless IP Camera, Smartphone, Tabl …
  • LTE Insights Service -The LTE Ecosystem: A Global Analysis of Deployments, Subscriptions, Devices and Operator Strategies
    With over 36 fully commercial network launches and 150 LTE-enabled devices available in the market, LTE adoption has considerably gained momentum throughout the globe. Swedish incumbent operator Telia was the first to launch LTE services in December 2009. This was followed by several commercial laun …
  • スマートコネクティッド洗濯機のヨーロッパ市場分析
    The Europe Smart Connected Washing Machine Market would witness market growth of 22.1% CAGR during the forecast period (2017 – 2023).Washing machines are used is washing purposes, therefore, these machines save time and energy. Innovations in technology has led to the development of smart connected …
  • 世界の鉱山産業における水処理・廃水処理装置市場
    About Water and Waste Water Market in Mining Industry Water is extremely important in the processing of ore extracted in the Mining industry. Many of the mining facilities in the world are located in regions with a low source of water. These facilities face water-related issues arising at almost eve …
  • 世界及び中国のジフェニルホスホリルクロリド市場2015
    The 'Global and Chinese Diphenylphosphoryl Chloride Industry, 2010-2020 Market Research Report' is a professional and in-depth study on the current state of the global Diphenylphosphoryl Chloride industry with a focus on the Chinese market. The report provides key statistics on the market status of …
  • 世界の顔認識市場2016
    2016 Global Facial Recognition Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Facial Recognition industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and Ch …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIPR2016114 )"化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia):治療薬開発パイプライン動向2018" (英文:Chemotherapy Induced Neutropenia-Pipeline Insights, 2018)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。